Email updates

Keep up to date with the latest news and content from Journal of Cheminformatics and Chemistry Central.

This article is part of the supplement: 8th German Conference on Chemoinformatics: 26 CIC-Workshop

Open Access Poster presentation

Experimental validation of in silico target predictions on synergistic protein targets

Isidro Cortes-Ciriano1, Alexios Koutsoukas2, Olga Abian13, Andreas Bender2* and Adrian Velazquez-Campoy14*

Author Affiliations

1 Institute of Biocomputation and Physics of Complex Systems (BIFI), Unidad Asociada IQFR-CSIC-BIFI, and Department of Biochemistry and Molecular and Cellular Biology, Universidad de Zaragoza, Zaragoza, Spain

2 Unilever Centre for Molecular Science Informatics, Chemistry Department, University of Cambridge, Cambridge CB2 1EW, UK

3 Aragon Health Sciences Institute (I+CS), Zaragoza, Spain

4 Fundacion ARAID, Diputacion General de Aragon, Spain

For all author emails, please log on.

Journal of Cheminformatics 2013, 5(Suppl 1):P31  doi:10.1186/1758-2946-5-S1-P31

The electronic version of this article is the complete one and can be found online at: http://www.jcheminf.com/content/5/S1/P31


Published:22 March 2013

© 2013 Cortes-Ciriano et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Poster presentation

Two trends are apparent in current early-stage drug discovery settings, firstly a revival of phenotypic screening strategies [1], and secondly the increasing acceptance that drugs modulate multiple targets in parallel ('multi-target drugs') [2].The work presented here combines those aspects by integrating experimental phenotypic screening for cytotoxic compounds with an experimental validation of individual protein targets modulated by the compounds. In silico target predictions for a dataset comprising cytotoxic compounds showed an enrichment of crucial enzymes for the cell cycle (such as Topoisomerase I, Bcl-X and protein kinase C alpha) and for the defense against xenobiotics (such as P-gp 1 and CYP450 enzymes). Subsequently, ten compounds from an external library (HitFinder) predicted to be active on two of the enriched targets, P-glycoprotein 1 and Topoisomerase I, were tested in vitro. Hoechst 33342 dye uptake, P-gp ATPase activity and Topoisomerase I DNA relaxation assays were able to identify two inhibitors of P-gp with IC50 values of 37 ± 5 and 28 ± 2 μM, respectively, comparable to the activity of Verapamil (12 μM). Also identified were five moderate inhibitors of Topoisomerase I inhibitors, four of which produce a synergistic effect in HeLa cell cultures in the presence of the aforesaid P-gp inhibitors (two independent samples t-test, p<0.01). Hence, this appears to be the first study work where multiple aspects of compound action - phenotypic effect as well as activity on multiple protein targets - were prospectively validated, and where partial compound synergism could be experimentally confirmed.

References

  1. Swinney DC, Anthony J: How were new medicines discovered?

    Nat Rev Drug Discov 2011, 10:507-519. PubMed Abstract | Publisher Full Text OpenURL

  2. Hopkins AL: Network pharmacology.

    Nat Biotechnol 2007, 25:1110-1111. PubMed Abstract | Publisher Full Text OpenURL